Loading...
Preeclampsia's burden to mother and newborn is great, both in the U.S. and worldwide. Although the disorder often strikes nulliparous women with no risk factors, some clinical characteristics portend excess risk. The U.S. Preventive Services Task Force (USPSTF) has completed a systematic review of 27 randomized, placebo-controlled trials assessing the benefits of low-dose aspirin (range, 50–150 mg daily) for the prevention of preeclampsia and its sequelae among women at higher-than-average risk for the condition.
On balance, the trials demonstrated a reduction in risk for preeclampsia (relative risk, 0.76; 95% confidence interval, 0.62–0.95), fetal growth restriction (RR, 0.80; 95% CI, 0.65–0.99) and preterm birth (RR, 0.86; 95% CI, 0.76–0.9…